3D human microvessel-on-a-chip model for studying monocyte-to-endothelium adhesion under flow - application in systems toxicology.


Journal

ALTEX
ISSN: 1868-8551
Titre abrégé: ALTEX
Pays: Germany
ID NLM: 100953980

Informations de publication

Date de publication:
2020
Historique:
received: 30 11 2018
accepted: 15 08 2019
entrez: 25 8 2019
pubmed: 25 8 2019
medline: 25 11 2020
Statut: ppublish

Résumé

Lifestyle and genetic factors can lead to the development of atherosclerosis and, ultimately, cardiovascular adverse events. Rodent models are commonly used to investigate mechanism(s) of atherogenesis. However, the 3Rs principles, aiming to limit animal testing, encourage the scientific community to develop new physiologically relevant in vitro alternatives. Leveraging the 96-chip OrganoPlate®, a microfluidic platform, we have established a three-dimensional (3D) model of endothelial microvessels-on-a-chip under flow using primary human coronary arterial endothelial cells. As functional readout, we have set up an assay to measure the adhesion of monocytes to the lumen of perfused microvessels. For monitoring molecular changes in microvessels, we have established the staining and quantification of specific protein markers of inflammation and oxidative stress using high content imaging, as well as analyzed transcriptome changes using microarrays. To demonstrate its usefulness in systems toxicology, we leveraged our 3D vasculature-on-a-chip model to assess the impact of the Tobacco Heating System (THS) 2.2, a candidate modified risk tobacco product, and the 3R4F reference cigarette on the adhesion of monocytic cells to endothelial microvessels. Our results show that THS 2.2 aerosol-conditioned medium had a reduced effect on monocyte-endothelium adhesion compared with 3R4F smoke-conditioned medium. In conclusion, we have established a relevant 3D vasculature-on-a-chip model for investigating leukocyte-endothelial microvessel adhesion. A case study illustrates how the model can be used for product testing in the context of systems toxicology-based risk assessment. The current model and its potential further development options also open perspectives of applications in vascular disease research and drug discovery.

Identifiants

pubmed: 31445503
doi: 10.14573/altex.1811301
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

47-63

Auteurs

Carine Poussin (C)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Bart Kramer (B)

MIMETAS BV, Leiden, The Netherlands.

Henriette L Lanz (HL)

MIMETAS BV, Leiden, The Netherlands.

Angelique Van den Heuvel (A)

MIMETAS BV, Leiden, The Netherlands.

Alexandra Laurent (A)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Thomas Olivier (T)

MIMETAS BV, Leiden, The Netherlands.

Marjolein Vermeer (M)

MIMETAS BV, Leiden, The Netherlands.

Dariusz Peric (D)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Karine Baumer (K)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Rémi Dulize (R)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Emmanuel Guedj (E)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Nikolai V Ivanov (NV)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Manuel C Peitsch (MC)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Julia Hoeng (J)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Jos Joore (J)

MIMETAS BV, Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH